Agenus swings to Q2 FY26 net loss of $0.6 million; revenue rises 34.24% to $34.5 million year-over-year
AGEN•Cash position and financing support Phase 3 trial plans
Cash and cash equivalents ended Q2 at $18.7 million; a July private placement added about $85 million in gross cash proceeds.
Management said the financing supports the planned Phase 3 ROBBIN trial of BOT+BAL, with first patient dosing expected in Q1 2027.
Q2 results improve on higher revenue and operating income
Agenus posted Q2 revenue of $34.5 million, up 34.24% from $25.7 million a year earlier.
Operating income was $11.3 million, swinging from an operating loss of $16.7 million in Q2 2025.
Net income was a loss of $0.6 million, improving from a net loss of $30 million a year earlier.
